Lee Jennifer Kayden
EVP, Head of North America
Lee Jennifer Kayden has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Aug 14, 2026.
On the most recent filing, Lee Jennifer Kayden is listed as EVP, Head of North America at RHYTHM PHARMACEUTICALS, INC. Inside the rolling window, Lee Jennifer Kayden reported no open-market purchases and 1 open-market sale totaling $8.9M in RYTM.
Companies traded
Other insiders at RYTM
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$8.9M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Lee Jennifer Kayden made?
Lee Jennifer Kayden has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.
Which companies does Lee Jennifer Kayden trade?
Lee Jennifer Kayden has filed SEC Form 4 disclosures for 1 company, including RYTM.
When was Lee Jennifer Kayden's most recent SEC Form 4 filing?
Lee Jennifer Kayden's most recent SEC Form 4 filing on Tracefour is dated Aug 14, 2026.
What is Lee Jennifer Kayden's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Lee Jennifer Kayden is listed as EVP, Head of North America.
What is Lee Jennifer Kayden's total buy and sell value in the current window?
Inside the rolling retention window, Lee Jennifer Kayden bought $0 and sold $8.9M based on SEC Form 4 filings.
What was Lee Jennifer Kayden's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 75,834 RYTM shares on 2026-08-13, worth $8.9M, per SEC Form 4 filings.